news
EU court rules GSK committed ‘pay-for-delay’ in paroxetine case
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
List view / Grid view
GlaxoSmithKline (GSK)
news
GSK halts Excedrin production due to manufacturing inconsistencies
GlaxoSmithKline has announced that it will not be manufacturing or distributing some of its Excedrin products after inconsistencies in ingredient transfer and weight.
article
The biggest pharma merger and acquisition deals of 2019
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
article
Intellectual property, divestments, fragmentation and the future: M&A in life sciences
Mergers and acquisitions in any market can define the landscape for its players. In this article, Emma Danks of Taylor Wessing reflects on recent M&A activity in the biopharmaceutical industry, highlighting influencing trends and what this might mean for the future.
news
Candidate vaccine shows sustained protection against pulmonary TB
A candidate TB vaccine’s efficacy level and acceptable safety profile have been confirmed in a three-year clinical trial.
article
Developing new antibiotics – essential research should not be a question of money
Why has the pharma industry and its talents lost interest in developing new antibiotics?
news
MHRA announces recall of Zantac products made by GSK
The UK MHRA has issued an alert for the recall of unexpired Zantac products made by GSK due to the possible contamination of ranitidine in the medicines.
news
Treatment approved for young children with severe eosinophilic asthma
Nucala is the first biologic approved in the US for six- to 11-year-old children with severe eosinophilic asthma by the FDA.
news
Kenya launches phased malaria vaccine pilot programme
Kenya has become the third African country to introduce the world’s first malaria vaccine into the country, in a phased pilot programme.
news
Global cephalosporin drugs market projected to rise 3.34 percent
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
article
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
news
Phase III programme for the use of otilimab for rheumatoid arthritis launched
A Phase III clinical development programme testing otilimab in patients with RA has begun.
news
GSK reported to have started the sale of $1.2 billion consumer health drugs
According to Reuters, GSK has started the sale of some consumer health brands as it seeks to raise £1 billion.
article
Microbiology In-Depth Focus 2019
The work of a pharmaceutical scientist requires precision, attention to detail and is of vital importance to the safety of products and ultimately patients. This section features insights from experienced scientists who’ve worked extensively in microbiological analysis, developing tests, methods and standards that help establish a foundation for the production…
news
$100 million is to be invested to increase vaccine manufacturing in US
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
